AGILVAX
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within the industry, academia, and the government sector through NIAID.
AGILVAX
Industry:
Biotechnology Health Care Medical
Founded:
2011-01-01
Address:
Albuquerque, New Mexico, United States
Country:
United States
Website Url:
http://www.agilvax.com
Total Employee:
11+
Status:
Closed
Contact:
5057974531
Email Addresses:
[email protected]
Total Funding:
8.3 M USD
Technology used in webpage:
IPv6 Cloudflare Hosting Person Schema Gravatar Profiles Cloudflare DNS
Similar Organizations
Affinivax
Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.
ArrePath
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
National Cancer Institute SBIR Development Center
National Cancer Institute SBIR Development Center investment in Grant - Agilvax
National Cancer Research Institute
National Cancer Research Institute investment in Grant - Agilvax
Sun Mountain Capital
Sun Mountain Capital investment in Series A - Agilvax
J. Hunt Holdings
J. Hunt Holdings investment in Series A - Agilvax
J. Hunt Holdings
J. Hunt Holdings investment in Series A - Agilvax
Official Site Inspections
http://www.agilvax.com
- Host name: 104.21.33.39
- IP address: 104.21.33.39
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Agilvax"
Agilvax - Crunchbase Company Profile & Funding
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity …See details»
Agilvax Company Profile 2024: Valuation, Funding & Investors
Agilvax General Information Description. Developer of a biotechnology platform designed to offer targeted antibody-based cancer immunotherapies and vaccines for fighting cancer. The …See details»
Agilvax Company Profile - Office Locations, Competitors ... - Craft
AgilVax is a biotech company discovering and developing targeted antibody-based therapeutics for metastatic cancer. It offers an antibody-drug conjugate, xCT-ADC, that targets xCT …See details»
Agilvax Inc - Company Profile and News - Bloomberg Markets
Company profile page for Agilvax Inc including stock price, company news, executives, board members, and contact informationSee details»
New Mexico Startup Agilvax Moves to Phase II of SBIR Grant
May 29, 2019 Phase II is focused on studies that support an Investigational New Drug (IND) application for AgilVax’s lead product, AX09. As a result of the grant award, AgilVax selected a …See details»
Agilvax, Inc. Company Profile | Albuquerque, NM | Competitors ...
Find company research, competitor information, contact details & financial data for Agilvax, Inc. of Albuquerque, NM. Get the latest business insights from Dun & Bradstreet.See details»
Albuquerque Biotech Company Agilvax Appoints Executive …
Nov 13, 2018 Local biotech company Agilvax, Inc., headquartered in Albuquerque, is commercializing a virus-like particle (VLP) technology platform, developed by researchers Dr. …See details»
Agilvax Inc. - BioCentury Company Profiles - BCIQ
Jul 26, 2019 Agilvax Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Albuquerque Biotech Company Agilvax Welcomes Prestigious …
Jan 16, 2019 Local biotech company Agilvax, Inc., headquartered in Albuquerque, is commercializing a virus-like particle (VLP) technology platform, developed by researchers Dr. …See details»
Agilvax, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Agilvax, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news, and 5 literature, Disease Domain:Neoplasms, Technology Platform:Drug ...See details»
AgilVax Appoints Dr. Joseph Patti as Chief Executive Officer
Jul 25, 2019 AgilVax Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and …See details»
Research programme: virus-like particles - Agilvax - AdisInsight
May 28, 2021 Agilvax is developing vaccines and immunotherapies for the prophylaxis of infectious diseases and cancer, utilising its proprietary virus-like particle (VLP) Research …See details»
Agilvax Announces Strategic Collaboration with Humabs BioMed …
Feb 17, 2015 Agilvax President & CEO, Dr. Federica Pericle stated, "Agilvax is committed to developing and increasing accessibility to targeted vaccines and immunotherapies. The …See details»
Abstract 5572: AX09: an immunotherapy candidate targeting the …
Jul 1, 2017 Agilvax has developed a novel immunotherapy candidate (AX09) based on our virus-like-particle technology for the treatment and prevention of metastatic breast cancer that …See details»
A Virus-Like-Particle immunotherapy targeting Epitope-Specific …
Dec 6, 2017 Virus-like particle (VLP) vaccines generate strong immune responses 29 due to their optimal size, particulate nature, and potent intrinsic adjuvant activity. 30 Agilvax's VLP …See details»
Local Biotech Company Agilvax’s Cancer Immunotherapy …
Jul 10, 2018 Local start-up company Agilvax, Inc., headquartered in Albuquerque, is commercializing a virus-like particle (VLP) technology platform developed by UNM …See details»
A Novel Immunotherapy Targeting Cancer Stem Cells for the
Aug 1, 2020 Agilvax?s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) …See details»
Anti-xCT antibody-radiopharmaceutical conjugate - AgilVax
An antibody conjugated radiopharmaceutical, designated as xCT-mAb-Rad, is being developed by AgilVax, for the diagnosis and treatment of various solid tumours Anti-xCT antibody …See details»
Agilvax - Company Profile - Tracxn
Jan 8, 2024 Agilvax - Developing stem cell immunotherapies for cancer. Raised a total funding of $6.5M over 5 rounds from 6 investors. Agilvax has 2850 competitors.See details»
Anti-xCT antibody-drug conjugate - Agilvax - AdisInsight - Springer
Nov 29, 2019 An antibody-drug conjugate targeting xCT (SLC7A11) is being developed by Agilvax for the treatment of cancer. Cancer cells upregulate xCT (a cystine-glutamate Anti-xCT …See details»